中文摘要：

目的探讨急性冠脉综合征患者普罗布考治疗前后血脂水平、血清氧化低密度脂蛋白（ox-LDL）、基质金属蛋白酶（MMP-2和MMP-9）水平的变化。方法选择急性冠脉综合征住院患者82例,随机分为普罗布考治疗组40例和对照组42例,两组患者均应用常规基础治疗,治疗组加用普罗布考口服。分别于治疗前和治疗4周后抽血查血脂、氧化低密度脂蛋白含量,治疗前和治疗后第3天、7天时血清基质金属蛋白酶（MMP-2和MMP-9）含量。结果同对照组比较,普罗布考治疗组总胆固醇（TC）、低密度脂蛋白（LDL）及甘油三酯（TG）均明显降低;同时普罗布考治疗组氧化低密度脂蛋白（ox-LDL）血清MMP-2和MMP-9含量也明显降低,差异均有统计学意义（P〈0.05）。两组患者均未出现严重不良反应。结论普罗布考不仅能有效降低急性冠脉综合征患者的血清TC和LDL水平,同时还能显著降低血清ox-LDL及血清MMP-2和MMP-9水平,具有抗氧化及抗炎作用。

英文摘要：

Objective To investigate the changes of blood lipid levels,oxidized low density lipoprotein（ox-LDL）and matrix metalloproteinase（MMP-2 and MMP-9） before and after probucol treatment on patients with acute coronary syndromes. Methods 82 patients were randomly divided into treatment group（n=40）and control group（n =42）. Apply the routine therapy to both groups and the patients in treatment group took additional probucol. The blood lipid and oxidized low density lipoprotein were measured before the treatment and 4 weeks after treatment. The matrix metalloproteinase was measured before the treatment,on the third day and seventh day after treatment. Results Compared with the control group,the treatment group levels of total cholesterol（TC）,low density lipoprotein（LDL）and triglycerides（TG） decreased significantly（P0. 05）;besides,the levels of oxidized low density lipoprotein（ox-LDL）and matrix metalloproteinase（MMP-2 and MMP-9） decreased significantly（P0. 05）. No severe adverse effects were observed in both groups during the therapy. Conclusions Probucol could not only reduce the TC and LDL levels of the acute coronary syndromes patients,but also reduce the ox-LDL and MMP-2 and MMP-9 levels significantly,indicating its good effect of anti-oxidation and anti-inflammatory.